104 related articles for article (PubMed ID: 1777244)
1. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Ljungberg A; Hjelm AL; Fagerberg J; Lindemalm C; Osterborg A; Wersäll P
Acta Oncol; 1991; 30(8):923-31. PubMed ID: 1777244
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
3. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).
Ragnhammar P; Magnusson I; Masucci G; Mellstedt H
Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997
[TBL] [Abstract][Full Text] [Related]
5. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
7. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
9. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
10. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
11. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf IG
Z Gastroenterol; 2000 Aug; 38(8):615-22. PubMed ID: 11031784
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
[TBL] [Abstract][Full Text] [Related]
14. MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
Frödin JE; Fagerberg J; Hjelm Skog AL; Liljefors M; Ragnhammar P; Mellstedt H
Hybrid Hybridomics; 2002 Apr; 21(2):99-101. PubMed ID: 12031098
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Fukuda M; Horibe K; Furukawa K
Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
[TBL] [Abstract][Full Text] [Related]
16. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
[TBL] [Abstract][Full Text] [Related]
17. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).
Masucci G; Lindemalm C; Frödin JE; Hagström B; Mellstedt H
Hybridoma; 1988 Oct; 7(5):429-40. PubMed ID: 3198133
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
Ragnhammar P
Med Oncol; 1996 Sep; 13(3):167-76. PubMed ID: 9106176
[TBL] [Abstract][Full Text] [Related]
20. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
